GT Biopharma (NASDAQ:GTBP) Upgraded to “Strong-Buy” at Roth Capital

GT Biopharma (NASDAQ:GTBP) was upgraded by research analysts at Roth Capital to a “strong-buy” rating in a report released on Monday,Zacks.com reports. Roth Capital also issued estimates for GT Biopharma’s Q4 2024 earnings at ($1.55) EPS, Q1 2025 earnings at ($0.59) EPS, Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.47) EPS, FY2027 earnings at ($1.42) EPS and FY2028 earnings at ($1.21) EPS.

Separately, Roth Mkm began coverage on GT Biopharma in a report on Monday. They set a “buy” rating and a $11.00 target price on the stock.

GT Biopharma Price Performance

Shares of NASDAQ GTBP opened at $2.79 on Monday. The business has a 50 day simple moving average of $2.66 and a 200 day simple moving average of $2.74. GT Biopharma has a 52 week low of $1.92 and a 52 week high of $10.66.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.